How long after breast cancer surgery can I take neratinib/neratinib tablets?

Neratinib/Neratinib is a targeted therapy called an irreversible pan-HER inhibitor, used to treat HER2-positive breast cancer. Neratinib can be used to treat early-stage HER2-positive breast cancer for a long time after surgery (what doctors call long-term adjuvant therapy). Patients take neratinib within 2 years after undergoing surgery and completing a chemotherapy regimen including Herceptin (chemical name: trastuzumab). Neratinib is also used in combination with the chemotherapy drug Xeloda (chemical name: capecitabine) to treat advanced and metastatic HER2-positive breast cancer in patients who have received at least two HER2 inhibitors for advanced disease.

HER2-positive breast cancer produces too much HER2 protein. The HER2 protein sits on the surface of cancer cells and receives signals that tell the cancer to grow and spread. About one-quarter of breast cancer patients are HER2-positive. HER2-positive breast cancers tend to be more aggressive and more difficult to treat than HER2-negative breast cancers. Neratinib is an irreversible pan-HER inhibitor that fights HER2-positive breast cancer by blocking the ability of cancer cells to receive growth signals. When treating early-stage HER2-positive breast cancer, patients can take neratinib for 1 year; when treating advanced or metastatic HER2-positive breast cancer, patients can continue taking neratinib as long as they benefit from the drug and have no disturbing side effects.

A doctor's evaluation and advice must be obtained before taking neratinib. The treatment of breast cancer is a complex process that requires comprehensive consideration of the patient's condition, the effects and side effects of the treatment plan, and other factors. Therefore, before starting to take neratinib, please have detailed communication and consultation with your doctor to ensure whether the drug is suitable for your treatment needs.